Sugi Predict

Sugi Predict / Compounds / SCHEMBL485294

SCHEMBL485294

SCHEMBL485294

ClCc1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.53
▸ RAB9A P51151 6/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ POLB P06746 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ EGFR P00533 2/20 0.43
▸ IDO1 P14902 1/20 0.43
▸ F10 P00742 1/20 0.42
▸ HRH4 Q9H3N8 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ F7 P08709 1/20 0.41
▸ LTA4H P09960 1/20 0.41
▸ F3 P13726 1/20 0.41
▸ AHR P35869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30040705 0.85 TDP1 (0.72) TDP1RAB9AKDM4ESMN1; SMN2NPC1
SCHEMBL656416 0.85 TDP1 (0.72) TDP1RAB9AKDM4ESMN1; SMN2NPC1
SCHEMBL18291859 0.84 TDP1 (0.51) TDP1RAB9AKDM4ESMN1; SMN2GAA
SCHEMBL1050352 0.84 TDP1 (0.75) TDP1RAB9ASMN1; SMN2GAAHTT
SCHEMBL5100448 0.84 TDP1 (0.51) TDP1RAB9AKDM4ESMN1; SMN2LMNA
SCHEMBL7764723 0.84 GAA (0.64) TDP1RAB9ASMN1; SMN2GAAHTT
SCHEMBL4151145 0.84 TDP1 (0.51) TDP1RAB9AKDM4ESMN1; SMN2GAA
Hydrochloric Acid SCHEMBL4148629 0.82 TDP1 (0.50) TDP1RAB9AKDM4ESMN1; SMN2GAA
Hydrochloric Acid SCHEMBL30012925 0.82 TDP1 (0.50) TDP1RAB9AKDM4ESMN1; SMN2GAA
Hydrochloric Acid SCHEMBL5204712 0.82 TDP1 (0.50) TDP1RAB9AKDM4ESMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3364967-B1 FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2026-05-20 — — EP disclosed
US-20230117034-A1 PYRAZOLOTRIAZINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-20 — — US disclosed
EP-4073072-A1 PYRAZOLOTRIAZINES Bayer Aktiengesellschaft (DE) 2022-10-19 — — EP disclosed
CN-115023427-A Pyrazolotriazines 拜耳公司 2022-09-06 — — CN disclosed
WO-2021116178-A1 PYRAZOLOTRIAZINES BAYER AKTIENGESELLSCHAFT (DE) 2021-06-17 — — WO disclosed
US-10738041-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2020-08-11 — — US disclosed
US-20180297991-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2018-10-18 — — US disclosed
EP-3364967-A2 FERROPORTIN INHIBITORS Vifor (International) AG (CH) 2018-08-29 — — EP disclosed
US-9884832-B2 Inhibitors targeting drug-resistant influenza A THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-02-06 — — US disclosed
US-9884832-B2 Inhibitors targeting drug-resistant influenza A THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-02-06 — — US disclosed
US-20080090854-A1 CXCR2 INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-17 — — US disclosed
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 — — US disclosed
CN-1420882-A Substd. oxoazaheterocyclyl compounds AVENTIS PHARM PROD INC (US) 2003-05-28 — — CN disclosed
EP-1051176-A4 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARM PROD INC (US) 2002-06-12 — — EP disclosed
EP-1208097-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS Aventis Pharmaceuticals Inc. (US) 2002-05-29 — — EP disclosed
CN-1291892-A Substituted oxoazaheterocyclyl factor Xa inhibitors AWENTIS PHARMACEUTICAL INC (US) 2001-04-18 — — CN disclosed
WO-2001007436-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS AVENTIS PHARMACEUTICALS INC. (US) 2001-02-01 — — WO disclosed
EP-1051176-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2000-11-15 — — EP disclosed
WO-2000032590-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-06-08 — — WO disclosed
WO-1999037304-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds F13B, F9, F11 TDP1 3183/4885RAB9A 1986/4885KDM4E 2943/4885
US-20230117034-A1 PYRAZOLOTRIAZINES BRCA1, TPX2, CCND2 TDP1 374/4885RAB9A 3297/4885KDM4E 2973/4885
US-10738041-B2 Ferroportin inhibitors SLC40A1, HAMP, TFRC TDP1 4275/4885RAB9A 2727/4885KDM4E 4724/4885
US-20180297991-A1 Novel Ferroportin Inhibitors SLC40A1, HAMP, TFRC TDP1 4231/4885RAB9A 2357/4885KDM4E 4732/4885
US-20080090854-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR4 TDP1 2080/4885RAB9A 1404/4885KDM4E 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.